GDRX · Goodrx Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $194.01M | - | $196.03M | $203.07M | $202.97M | - | $195.25M | $200.61M | $197.88M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $30.18M | - | $31.01M | $29.93M | $31.14M | - | $30.14M | $30.85M | $31.02M | - |
| SG&A | $26.82M | - | $32.01M | $28.38M | $29.63M | - | $25.62M | $27.59M | $41.11M | - |
| Total Operating Expenses | $180.00M | - | $181.41M | $176.26M | $179.59M | - | $174.84M | $180.73M | $190.50M | - |
| D&A | $21.79M | - | $21.43M | $19.73M | $20.91M | - | $17.54M | $16.96M | $15.94M | - |
| Operating Income | $14.01M | - | $14.62M | $26.81M | $23.38M | - | $20.41M | $19.88M | $7.38M | - |
| Interest Expense | $9.77M | - | $10.83M | $14.57M | $14.64M | - | $14.72M | $14.57M | $14.64M | - |
| Income Tax | $4.47M | - | $4.98M | $6.73M | $5.62M | - | $4.15M | $4.95M | $1.30M | - |
| Net Income | $1.17M | - | $1.12M | $12.84M | $11.05M | - | $3.96M | $6.69M | ($1.01M) | - |
| EPS - Basic | $0.00 | - | $0.00 | $0.04 | $0.03 | - | $0.01 | $0.02 | $0.00 | - |
| EPS - Diluted | $0.00 | - | $0.00 | $0.04 | $0.03 | - | $0.01 | $0.02 | $0.00 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $235.71M | $261.82M | $273.53M | $281.32M | $300.98M | $448.35M | $423.78M | $524.90M | $533.29M | $672.30M |
| Accounts Receivable | $232.72M | $235.75M | $203.74M | $189.03M | $160.12M | $145.93M | $130.80M | $161.77M | $144.77M | $143.61M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $14.53M | $19.41M | $28.73M | $25.41M | $15.26M | $14.14M | $12.39M | $16.88M | $33.52M | $36.27M |
| Current Assets | $1.27B | $643.10M | $565.51M | $550.61M | $540.21M | $659.25M | $626.80M | $750.55M | $732.80M | $872.79M |
| Total Assets | $2.02B | $1.40B | $1.33B | $1.32B | $1.30B | $1.39B | $1.35B | $1.48B | $1.45B | $1.59B |
| Current Liabilities | $859.20M | $246.00M | $181.86M | $130.91M | $103.38M | $123.90M | $114.36M | $102.47M | $116.52M | $122.56M |
| Long-term Debt | $482.42M | $483.26M | $484.11M | $484.97M | $485.84M | $486.71M | $487.59M | $645.65M | $646.68M | $647.70M |
| Total Liabilities | $1.40B | $787.80M | $724.79M | $675.67M | $640.92M | $663.41M | $658.41M | $805.99M | $822.89M | $826.84M |
| Stockholders' Equity | $621.99M | $616.26M | $600.71M | $643.03M | $654.35M | $724.66M | $696.43M | $669.40M | $631.07M | $761.96M |
| Retained Earnings | ($1.41B) | ($1.41B) | ($1.42B) | ($1.42B) | ($1.43B) | ($1.44B) | ($1.45B) | ($1.45B) | ($1.46B) | ($1.46B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $11.84M | - | - | - | $9.41M | - | - | - | $42.59M | - |
| Investing Cash Flow | ($21.64M) | - | - | - | ($51.88M) | - | - | - | ($20.61M) | - |
| Financing Cash Flow | ($16.30M) | - | - | - | ($104.90M) | - | - | - | ($160.97M) | - |
| CapEx | $1.14M | - | - | - | $142.0K | - | - | - | $407.0K | - |
| Free Cash Flow | $10.70M | - | - | - | $9.27M | - | - | - | $42.18M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 7.2% | - | 7.5% | 13.2% | 11.5% | - | 10.5% | 9.9% | 3.7% | - |
| EBITDA margin | 18.5% | - | 18.4% | 22.9% | 21.8% | - | 19.4% | 18.4% | 11.8% | - |
| Net margin | 0.6% | - | 0.6% | 6.3% | 5.4% | - | 2.0% | 3.3% | -0.5% | - |
| Free cash flow margin | 5.5% | - | - | - | 4.6% | - | - | - | 21.3% | - |
| FCF / Net income | 9.15 | - | - | - | 0.84 | - | - | - | -41.80 | - |
| R&D / Revenue | 15.6% | - | 15.8% | 14.7% | 15.3% | - | 15.4% | 15.4% | 15.7% | - |
| SG&A / Revenue | 13.8% | - | 16.3% | 14.0% | 14.6% | - | 13.1% | 13.8% | 20.8% | - |
| Effective tax rate | 79.3% | - | 81.7% | 34.4% | 33.7% | - | 51.1% | 42.5% | 444.4% | - |
| Return on assets | 0.1% | - | 0.1% | 1.0% | 0.9% | - | 0.3% | 0.5% | -0.1% | - |
| Return on equity | 0.2% | - | 0.2% | 2.0% | 1.7% | - | 0.6% | 1.0% | -0.2% | - |
| Return on invested capital | 0.6% | - | 0.7% | 1.6% | 1.4% | - | 0.9% | 0.9% | 0.3% | - |
| Liquidity | ||||||||||
| Current ratio | 1.47 | 2.61 | 3.11 | 4.21 | 5.23 | 5.32 | 5.48 | 7.32 | 6.29 | 7.12 |
| Quick ratio | 1.47 | 2.61 | 3.11 | 4.21 | 5.23 | 5.32 | 5.48 | 7.32 | 6.29 | 7.12 |
| Cash ratio | 0.27 | 1.06 | 1.50 | 2.15 | 2.91 | 3.62 | 3.71 | 5.12 | 4.58 | 5.49 |
| Leverage | ||||||||||
| Debt / Equity | 0.78 | 0.78 | 0.81 | 0.75 | 0.74 | 0.67 | 0.70 | 0.96 | 1.02 | 0.85 |
| Debt / Assets | 0.24 | 0.34 | 0.37 | 0.37 | 0.38 | 0.35 | 0.36 | 0.44 | 0.44 | 0.41 |
| Debt / EBITDA | 13.48 | - | 13.43 | 10.42 | 10.97 | - | 12.85 | 17.52 | 27.73 | - |
| Interest coverage | 1.4x | - | 1.4x | 1.8x | 1.6x | - | 1.4x | 1.4x | 0.5x | - |
| Equity multiplier | 3.25 | 2.28 | 2.21 | 2.05 | 1.98 | 1.92 | 1.95 | 2.20 | 2.30 | 2.09 |
| Liabilities / Assets | 0.69 | 0.56 | 0.55 | 0.51 | 0.49 | 0.48 | 0.49 | 0.55 | 0.57 | 0.52 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.15 | 0.15 | 0.16 | - | 0.14 | 0.14 | 0.14 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 438d | - | 379d | 340d | 288d | - | 245d | 294d | 267d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 124.5x | 147.0x | - | 694.0x | 390.0x | - | - |
| P / B | 1.1x | - | 2.4x | 2.8x | 2.6x | - | 3.9x | 4.5x | 4.4x | - |
| P / S | 3.4x | - | 7.5x | 8.8x | 8.2x | - | 13.8x | 15.0x | 14.0x | - |
| EV / EBITDA | 25.6x | - | 46.7x | 42.6x | 42.0x | - | 72.7x | 84.7x | 123.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -4.4% | - | 0.4% | 1.2% | 2.6% | - | 8.5% | 5.8% | 7.6% | - |
| Revenue CAGR (3y) | 1.8% | - | 1.5% | 1.9% | -0.1% | - | 0.0% | 4.3% | 14.0% | - |
| Revenue CAGR (5y) | 7.8% | - | 6.9% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -40.1% | - | -28.4% | 34.9% | 216.8% | - | - | 8.6% | -34.7% | - |
| Net income growth (YoY) | -89.4% | - | -71.8% | 91.9% | - | - | - | -88.6% | 69.3% | - |
| EPS growth (YoY) | - | - | - | 100.0% | - | - | - | -85.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | 0.0% | - | - | -34.1% | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 15.4% | - | - | - | -78.0% | - | - | - | 31.2% | - |
| FCF CAGR (5y) | -24.9% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -4.9% | -15.0% | -13.7% | -3.9% | 3.7% | -4.9% | -21.0% | -25.2% | -23.7% | -6.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$796.85M totalPrescription Transactions Revenue$544.00M · 68.3%
Pharma Direct Revenue$151.38M · 19.0%
Subscription Revenue$83.79M · 10.5%
Other Revenue$17.69M · 2.2%
Peer comparison
Same SIC group: Services-Computer Processing & Data Preparation
Comparing GoodRx Holdings against the 5 most active filers in the same SIC group.